Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 6, 2000, Pages 719-725

  Gouzoulis Mayfrank, Euphrosyne ^a   Daumann, Jörg ^a   Tuchtenhagen, Frank ^a   Pelz, Susanne ^a   Becker, Steffanie ^a   Kunert, Hans Jürgen ^a   Fimm, Bruno ^b   Sass, Henning ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Department of Neurology ^*  (United Kingdom)

Author keywords

3,4 Methylenedioxymethamphetamine; Cognitive performance; Ecstasy; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; SEROTONIN;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE; FEMALE; HUMAN; INTELLIGENCE; LEARNING; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0034068677     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.6.719     Document Type: Article

References (44)

1. Ricaurte GA, Bryan G, Strauss L, et al. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985;22:986-8.
2. Battaglia G, Yeh SY, O'Hearn E, et al. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H] paroxetine-labelled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-16.
3. Schmidt CJ. Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur J Pharmacol 1987;136:81-8.
4. Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 1988; 29:269-74.
5. Ricaurte GA, Martello AL, Katz JL, et al. Lasting effects of MDMA on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 1992;261:616-22.
6. O'Hearn EG, Battaglia G, De Souza EB, et al. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988;8:2788-803.
7. Wilson MA, Ricaurte GA, Molliver ME. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylene amphetamine. Neuroscience 1989;28:121-37.
8. Molliver ME, Berger UV, Mamounas LA, et al. Neurotoxicity of MDMA and related compounds. Ann NY Acad Sci 1990;600:640-6.
9. Ricaurte GA, Forno LS, Wilson MA, et al. MDMA selectively damages central serotonergic neurons in the primate. JAMA 1988;260:51-5.
10. Fischer C, Hatzidimitriou G, Wlos J, et al. Reorganization of ascending 5-HAT axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxyamphetamine (MDMA, ecstasy). J Neurosci 1995;15:5476-85.
11. Hatzidimitriou G, McCann DU, Ricaurte G. Altered serotonin innervation patterns in the forebrain of monkeys treated with +/-3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999;19:5096-107.
12. McCann DU, Szabo Z, Scheffel U, et al. Positron emission tomographic evidence of toxic effect of MDMA (ecstasy) on brain serotonin neurons in human beings. Lancet 1998; 352:1433-7.
13. Soubrié P. Reconciling the role of the central serotonin neurons in human and animal behavior. Behav Brain Sci 1986; 9:319-64.
14. Altman HJ, Normile HJ. What is the nature of the role of the serotonergic nervous system in learning and memory: prospects for development of an effective treatment strategy for senile dementia. Neurobiol Aging 1988;9:627-38.
15. McEntee W, Crook T. Serotonin, memory and aging. Psychopharmacology 1991;103:143-9.
16. Sirvio J, Riekkinen P, Jakala P Jr, et al. Experimental studies on the role of serotonin in cognition. Prog Neurobiol 1994;43:363-79.
17. Robbins TW, Everitt BJ. Arousal systems and attention. In: Gazzaniga MS, ed. The cognitive neurosciences. London: MIT Press, 2nd printing, 1995:703-20.
18. Poulos CX, Parker JL, Le AD. Desfenfluramine and 8-OH-DPAT modulate impulsivity in a delay-of-reward paradigm: implications for a correspondence with alcohol consumption. Behav Pharmacol 1996;7:395-9.
19. Morgan MJ. Recreational use of ecstasy (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998;19:252-64.
20. Krystal JH, Price LH. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992;18:331-41.
21. Curran HV, Travill RA. Mood and cognitive effects of (3,4-methylenedioxymethamphetamine (MDMA, ecstasy): week-end high followed by mid-week low. Addiction 1997;92:821-31.
22. Parrott AC, Lees A, Garnham NJ, et al. Cognitive performance in recreational users of MDMA (ecstasy): evidence for memory deficits. J Psychopharmacol 1998;12:79-83.
23. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 1998;139:261-8.
24. Bolla KI, McCann DU, Ricaurte GA. Memory impairment in abstinent MDMA (ecstasy) users. Neurology 1998;51: 1532-7.
25. Morgan MJ. Memory deficits associated with recreational use of ecstasy (MDMA). Psychopharmacology 1999;141:30-6.
26. McCann DU, Mertl M, Eligulashvili V, et al. Cognitive performance in +/-3,4-methylenedioxymethamphetamine (MDMA, ecstasy) users: a controlled study. Psychopharmacology 1999;143:417-25.
27. Zimmermann P, Fimm B. Test for attentional performance (TAP). Herzogenrath: PsyTest, 1995.
28. Bäumler G. Farbe-Wort-Interferenztest FWIT. Göttingen: Hogreve, 1985.
29. Corsi AT. Human memory and the medial temporal region of the brain [dissertation]. Boston: McGill University, 1972.
30. Tewes U. HAWIE-R. Hamburg-Wechsler Intelligenztest für Erwachsene / Revision 1991. 2nd ed. Bern: Huber, 1991.
31. Helmstaedter C, Durwen HF. VLMT: Verbaler Lern - und Merkfähigkeitstest. Ein praktikables und differenziertes Instrumentarium zur Prüfung der verbalen Gedächtnisstungen. Schweiz Arch Neurol Psychiatr 1990;141:21-30.
32. Rey A. L'examen de clinique en psychologie. Paris: Presses Universitaires de France, 1964.
33. Hänsgen K-D, Merten Th. LEILA: Leistungsdiagnostisches Labor. 3rd ed. Göttingen: Hogreve, 1995.
34. Horn W. Leistungsprüfsystem L-P-S. 2nd ed. Göttingen: Hogreve, 1983.
35. Duncan J. Attention, intelligence and the frontal lobes. In: Gazzaniga MS, ed. The cognitive neurosciences. 2nd printing. London: MIT Press, 1995:721-33.
36. Cramon DY, Mai N, Ziegler W. Neuropsychologische Diagnostik. Weinheim: VCH Verlags gesellschaft, 1993.
37. Linnoila M, Virkkunen M, Scheinin M, et al. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non-impulsive violent behavior. Life Sci 1983;33:2609-14.
38. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 1989;46:587-99.
39. O'Keane V, Moloney E, O'Neilly, et al. Blunted prolactin responses to d-fenfluramine in sociopathy. Evidence for subsensitivity of a central serotonergic function. Br J Psychiatry 1992;160:643-6.
40. Virkkunen M, Linnoila M. Brain serotonin, type II alcoholism and impulsive violence. J Stud Alcohol 1993; 11 (suppl): 163-9.
41. Gerra G, Zaimovic A, Giucastro G, et al. Serotonergic function after 3,4-methylenedioxymethamphetamine (ecstasy) in humans. Intern Clin Psychopharmacol 1998;13:1-9.
42. Mc Cann DU, Ridenour A, Shaham Y, et al. Serotonin neurotoxicity after 3,4-methymethamphetamine (MDMA, ecstasy): a controlled study in humans. Neuropsychopharmacology 1994;10:129-38.
43. Baddeley A. Working memory. Science 1992;255:556-9.
44. Hasbroucq T, Rihet P, Blin O, et al. Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett 1997;229:204-8.